TLSA — Tiziana Life Sciences Share News
0.000.00%
Last trade - 00:00- $137.84m
- $134.28m
Brief: Tiziana Life Sciences Initiates Program To Develop Intranasal Foralumab In Type 1 Diabetes
Brief: Tiziana Life Sciences To Pursue Development Of Intranasal Foralumab For The Treatment Of Long COVID
U.S. STOCKS ON THE MOVE-AMC Entertainment, Trilogy Metals, Nogin
U.S. STOCKS ON THE MOVE-Duckhorn Portfolio, BullFrog AI, VBI Vaccines
U.S. STOCKS ON THE MOVE-Acuity Brands, Cardlytics, Tiziana
Tiziana rises on positive data from preclinical study on lead drug
Brief: Tiziana Life Sciences Announces Purchase Of Common Shares By Chairman And Acting CEO
Brief: Tiziana Life Sciences Announces Purchase Of Common Shares By Chairman And Acting CEO
Brief: Tiziana Life Sciences Announces Purchase Of Common Shares By Chairman, Acting CEO
Brief: Tiziana Life Sciences Announces IND Filed For Phase 2 Study Of Milciclib
Brief: Tiziana Life Sciences Announces Additional Clinical Improvements
Brief: Tiziana Life Sciences Updates Interim Results For Six Months Ended 30 June
Tiziana rises on completing lab safety study for lead drug
U.S. STOCKS ON THE MOVE-Trip.com, Verizon Communications, Netflix
U.S. STOCKS ON THE MOVE-Reviva, AbCellera, Verizon
Brief: Tiziana Life Sciences Announces Completion Of Prerequisite Pre-Clinical Safety Study
U.S. STOCKS ON THE MOVE-Core Scientific, gold miners, Cognizant
Brief: Tiziana Life Sciences Ltd. Granted 180-Day Extension By Nasdaq To Meet Minimum Bid Price Requirements
Brief: Tiziana Life Sciences To Focus On Intranasal Foralumab Central Nervous System Diseases